Discovery of New Early Detection Biomarkers of Acute Respiratory Distress Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02625064

Acronym

ARDS

Enrollment

500

Registered

2015-12-09

Start date

2016-01-31

Completion date

2019-01-31

Last updated

2015-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Keywords

ARDS, biomarkers, proteomic

Brief summary

The goal of this project is to find a series novel biomarkers by differential proteomic techniques that can improve the early diagnosis and develop a more efficient therapy to enhance ARDS patient survival rate.

Detailed description

Acute respiratory distress syndrome(ARDS) has a very poor prognosis and high mortality. To improve the early diagnosis of ARDS, there is an urgent need for novel biomarkers of ARDS. The goal of this project is to find a series novel biomarkers by differential proteomic techniques that can improve the early diagnosis and develop a more efficient therapy to enhance ARDS patient survival rate. Clinical data and blood sample were recorded before treatment and after treatment. Acute Physiology And Chronic Health Evaluation III (APACHE III) scores were calculated at enrolment. Studying blood specimens from different period ARDS patients by proteomic analysis. It can provide information on a complex composition of proteins that are differentially expressed, which could be used for discovering high sensitivity and specificity ARDS biomarker.

Interventions

OTHERBlood samples collection before treatment

OTHERBlood samples collection after treatment

OTHERlaboratory biomarker proteomic analysis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* The Berlin definition of acute respiratory distress syndrome * ATS definition of severe pneumonia

Exclusion criteria

* age below 18 years * pregnancy * Expected survival under 24 hours

Design outcomes

Primary

Measure	Time frame
Analysis of serum proteins directly by proteomics analysis to identify new biomarkers of ARDS	baseline

Secondary

Measure	Time frame
APACHE III score	baseline, 1week, 2 weeks
PaO2/FiO2 ratio	baseline, day 3, day 5, 1week, 2 weeks
Mortality or multi-organ failure	1 month

Countries

China

Contacts

Primary ContactPinhua Pan, MD, Doctor

pinhuapan668@126.com+86 13574810968

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026